US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

51.03

0.0000

Volume:- -

Turnover:- -

Market Cap:25.52M

PE:- -

High:51.03

Open:51.03

Low:51.03

Close:51.03

52wk High:57.06

52wk Low:50.07

Shares:500.00K

Float Shares:500.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor

ABBISKO-B (02256): ABBISK Medicine's CSF-1R Inhibitor Beijiemai® Approved by China's NMPA

Plus Therapeutics Expands CNSide Assay Platform to State of California

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Press Release: Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":51.03,"timestamp":1770411600000,"preClose":51.03,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Closed","change":0,"latestTime":"02-06 16:00:00 EST","open":51.03,"high":51.03,"low":51.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.03,"sharesOutstanding":500000,"nav":51.331892,"aum":25665950,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":51.03,"amplitude":0,"preClose":51.03,"low":51.03,"week52Low":50.07,"pbRate":"--","week52High":57.06,"institutionHeld":0,"latestPrice":51.03,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":51.03,"prevYearClose":51.03,"prevWeekClose":51.03,"prevMonthClose":51.03,"prevQuarterClose":51.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-24","symbol":"CSF","reason":null,"defaultRemindTime":1745501400000,"announcedDate":"2025-04-23","type":"delisting","dateTimestamp":1745467200000},{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-17","recordDate":"2017-01-19","paymentDate":"2017-01-20","value":0.0124628,"currency":"USD"},{"executeDate":"2017-02-14","recordDate":"2017-02-16","paymentDate":"2017-02-17","value":0.0180041,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-21","value":0.072161,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-19","value":0.02261,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-16","value":0.048374,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609868445","title":"Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™","url":"https://stock-news.laohu8.com/highlight/detail?id=2609868445","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609868445?lang=en_us&edition=fundamental","pubTime":"2026-02-06 03:00","pubTimestamp":1770318000,"startTime":"0","endTime":"0","summary":"Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness esta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233366/0/en/Denali-Therapeutics-Presents-Enzyme-TransportVehicle-Progress-Across-Three-Clinical-Programs-for-Treatment-of-Lysosomal-Storage-Disorders-at-2026-WORLDSymposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CSF","PRGS","ETV","BBB","BK4135","BK4100","BK4097","BK4007","TV","BK4539","GAA","LU2065732104.USD","CNS","LENZ"],"gpt_icon":0},{"id":"2608871508","title":"Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871508","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871508?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123600,"startTime":"0","endTime":"0","summary":"Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3230975/20739/en/Ultragenyx-Announces-Positive-Longer-Term-Data-Demonstrating-Treatment-with-UX111-Gene-Therapy-Results-in-Sustained-Significant-Reductions-in-CSF-HS-and-Continued-Meaningful-Improv.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF"],"gpt_icon":0},{"id":"2601315892","title":"Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287","url":"https://stock-news.laohu8.com/highlight/detail?id=2601315892","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601315892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700800,"startTime":"0","endTime":"0","summary":"Results to be discussed in KOL event today at 10 a.m. ETBETHESDA, Md., Jan.  06, 2026  (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213471/0/en/Gain-Therapeutics-Highlights-Biomarker-Evidence-Supporting-Disease-Modifying-Potential-of-GT-02287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","CSF","BK4119","LU1169589451.USD","BK4588","BK4139","GT","BK4585","PD","BK4023","GANX"],"gpt_icon":0},{"id":"2595975697","title":"The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595975697","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595975697?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:00","pubTimestamp":1767099600,"startTime":"0","endTime":"0","summary":"Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and nor","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/30/3211341/0/en/The-New-England-Journal-of-Medicine-Publishes-Phase-1-2-Study-of-Denali-Therapeutics-Tividenofusp-Alfa-DNL310-for-Hunter-Syndrome-MPS-II.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TV","BK4007","LENZ","BK4135","BK4100","BK4539","CSF","BK4139","CNS","BBB"],"gpt_icon":0},{"id":"2593048418","title":"Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor","url":"https://stock-news.laohu8.com/highlight/detail?id=2593048418","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593048418?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:29","pubTimestamp":1766402940,"startTime":"0","endTime":"0","summary":"Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically dev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/22/3209070/0/en/Abbisko-Therapeutics-CSF-1R-Inhibitor-Pimicotinib-Approved-by-the-China-NMPA-Addressing-the-Treatment-Gap-for-Tenosynovial-Giant-Cell-Tumor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CSF","BK4007","CR","BK4139","BK4081","ORR","LENZ","BK4539","EMA"],"gpt_icon":0},{"id":"1181395345","title":"ABBISKO-B (02256): ABBISK Medicine's CSF-1R Inhibitor Beijiemai® Approved by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1181395345","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181395345?lang=en_us&edition=fundamental","pubTime":"2025-12-22 16:41","pubTimestamp":1766392862,"startTime":"0","endTime":"0","summary":"On December 22, 2025, ABBISKO-B (02256) announced that its subsidiary, Shanghai ABBISK Biopharmaceutical Co., Ltd. (\"ABBISK Medicine\"), received approval from China's National Medical Products...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","02256","IE00B5MMRT66.SGD","LU2778985437.USD","BK1574","CSF","LU2476274720.SGD","BK1161","LU2476274308.USD","09939","BK1515","IE00B543WZ88.USD","LU2488822045.USD","159938"],"gpt_icon":0},{"id":"2590515350","title":"Plus Therapeutics Expands CNSide Assay Platform to State of California","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515350","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515350?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":"CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec.  11, 2025  (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203802/0/en/Plus-Therapeutics-Expands-CNSide-Assay-Platform-to-State-of-California.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","LU1883839398.USD","BK4007","CSF","CNS","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4585","BK4588","LU1894683264.USD","LU1894683348.USD","STT","LU0061475181.USD","IE0034235188.USD","BK4539","LENZ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2590134045","title":"AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2590134045","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590134045?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454400,"startTime":"0","endTime":"0","summary":"AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for the first time, that targeting underlying a-syn pathology with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203753/0/en/AC-Immune-Positive-Interim-Phase-2-Data-on-ACI-7104-056-Support-Potential-Slowing-of-Progression-of-Parkinson-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4113","BK4135","LU1169590202.USD","LU1169589451.USD","PD","ACIU","ACI","CSF","CNS","BK4139","BK4023"],"gpt_icon":0},{"id":"2588872548","title":"BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2588872548","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588872548?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856800,"startTime":"0","endTime":"0","summary":"BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199871/0/en/BioAge-Announces-Positive-Interim-Phase-1-Data-for-BGE-102-a-Novel-Brain-Penetrant-NLRP3-Inhibitor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF"],"gpt_icon":0},{"id":"2588186061","title":"New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2588186061","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588186061?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:40","pubTimestamp":1764711600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Dec.  02, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3198449/0/en/New-Data-Presented-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-lecanemab-irmb-on-Neurotoxic-A%CE%B2-Protofibrils-in-CSF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","CAA","AD","ARIA","MCI","CSF"],"gpt_icon":0},{"id":"2584394961","title":"Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584394961","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584394961?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:30","pubTimestamp":1763641800,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov.  20, 2025  (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary ofPlus Therapeutics, Inc.(Nasdaq:PSTV) (“Plus” or the “Company”), announced today that it has signed a n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191797/0/en/Plus-Therapeutics-Secures-National-Coverage-Agreement-with-Humana-for-CNSide-Cerebrospinal-Fluid-Assay-for-Metastatic-CNS-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","HUM","LU0417517546.SGD","CSF","SG9999014013.SGD","BK4539","CNS","LU0256863811.USD","BK4007","LU0170899867.USD","NHLD","LU0348723411.USD","LU0320765489.SGD","LU1093756168.USD","BK4135","BK4154","LU0238689110.USD","LU0070302665.USD","LU1093756325.SGD","BK4585","SG9999014005.SGD","LU0211331839.USD","BK4566","BK4139","BK4533","LU1983260115.SGD","LENZ","LU0390134368.USD","BK4588","SG9999014021.USD","LU0266013472.USD"],"gpt_icon":0},{"id":"2577282400","title":"Press Release: Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2577282400","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577282400?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:30","pubTimestamp":1761046200,"startTime":"0","endTime":"0","summary":"Appoints new leadership in commercial strategy and technical operations. HOUSTON, Oct. 21, 2025  -- Plus Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system  cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid  Tumor Cell Enumeration laboratory developed test .Recent accomplishments include expansion of the CNSide manufacturing footprint, advancements in commercial readiness and appointments in key leadership positions to propel the CNSide diagnostic business forward. To lead commercialization strategy, Russ Havranek, MS, MBA, has been promoted to Executive Vice President, Commercial and Corporate Strategy. In addition, Daniel Ortega, MBA, has been promoted to the position of Vice President, Development and Technical Operations to lead our diagnostic capabilities a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LENZ","STRK","BK4600","BK4139","BK4007","BK4585","BK4135","BK4516","CNS","BK4022","BK4596","BK4595","BK4023","PSTV","BK4539","BK4232","R","CSF"],"gpt_icon":1},{"id":"2574197687","title":"Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2574197687","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574197687?lang=en_us&edition=fundamental","pubTime":"2025-10-10 05:23","pubTimestamp":1760044980,"startTime":"0","endTime":"0","summary":"New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.   FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 —a pivotal biomarker in Alzheimer's disease research and other tauopathies. This first-of-its-kind assay is the only brain-derived single-plex solution available, setting a new benchmark for precision and CNS specificity in neurodegenerative disease research.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2792912/Alamar_Biosciences_Inc_NULISA_BD.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2792912/Alamar_Biosciences_Inc_NULISA_BD.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/alamar-biosciences-launches-nulisaqpcr-bd-ptau217-assay-a-breakthrough-in-non-invasive-brain-specific-biomarker-detection-for-alzheimers-disease-research-302580276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF.AU","CSF","BK7141"],"gpt_icon":0},{"id":"2574151683","title":"Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2574151683","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574151683?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:25","pubTimestamp":1760009100,"startTime":"0","endTime":"0","summary":"– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/09/3164032/0/en/Alterity-Therapeutics-Presents-Positive-Data-from-ATH434-Phase-2-Trial-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909916.SGD","LU2125909759.SGD","BK4139","BK4143","BK4007","LU1923622291.USD","CSF","ATHE","LENZ","LU0757428866.USD","LU2211815571.USD","BK4539","LU0053671581.USD","MSA","LU1815336091.USD","LU0728928796.USD"],"gpt_icon":0},{"id":"2573100726","title":"Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®","url":"https://stock-news.laohu8.com/highlight/detail?id=2573100726","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573100726?lang=en_us&edition=fundamental","pubTime":"2025-10-06 02:00","pubTimestamp":1759687200,"startTime":"0","endTime":"0","summary":"– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/05/3161349/0/en/Arvinas-Presents-Late-Breaking-Positive-Phase-1-Clinical-Data-for-ARV-102-a-PROTAC-LRRK2-Degrader-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF"],"gpt_icon":0},{"id":"2570094853","title":"Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit","url":"https://stock-news.laohu8.com/highlight/detail?id=2570094853","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570094853?lang=en_us&edition=fundamental","pubTime":"2025-09-25 19:31","pubTimestamp":1758799860,"startTime":"0","endTime":"0","summary":"CNSide Diagnostics, a wholly-owned subsidiary ofPlus Therapeutics, Inc. , has signed a national agreement with UnitedHealthcare insurance company, a unit of UnitedHealth Group Inc. .EffectiveSeptember 15, the agreement covers over 51 million people throughoutthe United States, providing the CNSide Cerebrospinal Fluid  Tumor Cell Enumeration laboratory developed test .The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.The superior clinical utility of CNSide over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.Also Read: Why Plus Therapeutics  Shares Are Exploding Higher. More than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.Last week, CNS","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/25/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/25/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/09/47861805/plus-therapeutics-national-coverage-agreement-with-unitedhealthcare-cns-cancer-diagnostic-kit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47861805/plus-therapeutics-national-coverage-agreement-with-unitedhealthcare-cns-cancer-diagnostic-kit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0787776722.HKD","LU0198837287.USD","IE00BZ1G4Q59.USD","LU0149725797.USD","LU0965509101.SGD","IE00BFSS8Q28.SGD","LU1988902786.USD","CNS","LU1506573853.SGD","SG9999014906.USD","IE00B4JS1V06.HKD","PSTV","SGXZ99366536.SGD","LU0342679015.USD","LU1854104046.USD","LU2112291526.USD","LU2552382215.SGD","SGXZ51526630.SGD","LU1064131342.USD","LU2461242641.AUD","LENZ","LU0310799852.SGD","LU0310800379.SGD","SG9999013999.USD","LU0094547139.USD","LU2125154778.USD","IE00B2B36J28.USD","LU0256863811.USD","LU1778281490.HKD","LU0211327993.USD","LU1066051498.USD","LU2491050071.SGD","SG9999014898.SGD","IE00B7KXQ091.USD","LU1551013425.SGD","LU0011850046.USD","IE000M9KFDE8.USD","LU2362541273.HKD","LU0128525689.USD","LU0353189680.USD","LU0158827948.USD","CSF","IE00BZ9MQY76.HKD","LU1814569148.SGD","LU0683600562.USD","LU2211815571.USD","IE00B894F039.SGD","LU0320765059.SGD","NHLD"],"gpt_icon":1},{"id":"2568471012","title":"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2568471012","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568471012?lang=en_us&edition=fundamental","pubTime":"2025-09-18 19:40","pubTimestamp":1758195600,"startTime":"0","endTime":"0","summary":"Biogen to drive end-to-end development and commercialization of ThecaFlex DRx, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs)ThecaFlex DRx has the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/18/3152321/0/en/Biogen-to-Acquire-Alcyone-Therapeutics-Expanding-Drug-Delivery-Solution-Portfolio-for-Key-Product-and-Pipeline-Candidates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LENZ","CSF","LU2362540622.SGD","BK4561","BK4588","BK4134","LU2517655291.USD","IT","LU2362541513.USD","LU2286300806.USD","BK4217","BK4539","IE00B894F039.SGD","BK4097","LU1814569148.SGD","LU2517655374.HKD","SMA","LU2362541273.HKD","ASO","LU0234570918.USD","LU2517655028.SGD","BK4135","BK4139","BK4560","BK4585","BK4200","LU0109394709.USD","LU0107464264.USD","LU0320765992.SGD","LU0889565916.HKD","S","BK4007","BK4532","SMN","BK4533","LU0154245673.USD","LU0154245756.USD","CNS"],"gpt_icon":0},{"id":"2563072015","title":"FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2563072015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563072015?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:00","pubTimestamp":1756501200,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/29/3141816/0/en/FDA-Approves-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HF","MCI","BK4080","AD","CDR","AAIC","BK4110","BK4132","CAA","ARIA","CSF"],"gpt_icon":0},{"id":"2559964326","title":"Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559964326","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559964326?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:15","pubTimestamp":1755202500,"startTime":"0","endTime":"0","summary":"Announced CNSide CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug.  14, 2025  (GLOBE NEWSWIRE) -- Plus Therapeu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133893/0/en/Plus-Therapeutics-Reports-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","CNS","BK4539","BK4135","NCI","CSF","BK4139","BK4202"],"gpt_icon":0},{"id":"2559795431","title":"Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2559795431","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559795431?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:30","pubTimestamp":1755171000,"startTime":"0","endTime":"0","summary":"CNSide can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide may catalyze LM treatment initiation, allow physicians to ada","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133364/0/en/Plus-Therapeutics-Presents-Positive-CNSide-CSF-Assay-Platform-Results-at-the-2025-SNO-ASCO-CNS-Metastases-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","CSF","LENZ","BK4139","BK4135","BK4539","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}]}}